Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
doi 10.17925/eor.2012.06.01.34
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

Ophthalmology
Ophthalmology
2014English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology
Ophthalmology
2016English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2013English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2016English

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Development and Testing of a Patient-Derived Questionnaire for Treatment of Neovascular Age-Related Macular Degeneration: Dimensions of Importance in Treatment of Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy